| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012 | 6002 | 2012 |
| Screening for epidermal growth factor receptor mutations in lung cancer R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ... New England Journal of Medicine 361 (10), 958-967, 2009 | 2965 | 2009 |
| Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... Lancet Oncol 13 (3), 239-246, 2012 | 627 | 2012 |
| BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer M Taron, R Rosell, E Felip, P Mendez, J Souglakos, MS Ronco, C Queralt, ... Human molecular genetics 13 (20), 2443-2449, 2004 | 468 | 2004 |
| Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation R Porta, JM Sanchez-Torres, L Paz-Ares, B Massuti, N Reguart, C Mayo, ... European Respiratory Journal 37 (3), 624-631, 2011 | 402 | 2011 |
| Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung … M Taron, Y Ichinose, R Rosell, T Mok, B Massuti, L Zamora, JL Mate, ... Clinical cancer research 11 (16), 5878-5885, 2005 | 392 | 2005 |
| Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non–small-cell lung cancer patients with EGFR mutations R Rosell, MA Molina, C Costa, S Simonetti, A Gimenez-Capitan, ... Clinical Cancer Research 17 (5), 1160-1168, 2011 | 358 | 2011 |
| Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients H Cortes-Funes, C Gomez, R Rosell, P Valero, C Garcia-Giron, A Velasco, ... Annals of oncology 16 (7), 1081-1086, 2005 | 286 | 2005 |
| Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial N Karachaliou, C Mayo-de las Casas, C Queralt, I de Aguirre, B Melloni, ... JAMA oncology 1 (2), 149-157, 2015 | 266 | 2015 |
| Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients R De las Peñas, M Sanchez-Ronco, V Alberola, M Taron, C Camps, ... Annals of Oncology 17 (4), 668-675, 2006 | 228 | 2006 |
| Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery R Rosell, E Felip, M Taron, J Majo, P Mendez, M Sanchez-Ronco, ... Clinical Cancer Research 10 (12), 4215s-4219s, 2004 | 212 | 2004 |
| Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients JL Ramirez, C Sarries, PL de Castro, B Roig, C Queralt, D Escuin, ... Cancer letters 193 (2), 207-216, 2003 | 159 | 2003 |
| Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC I Chaib, N Karachaliou, S Pilotto, J Codony Servat, X Cai, X Li, ... JNCI: Journal of the National Cancer Institute 109 (9), djx014, 2017 | 154 | 2017 |
| Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations I Garcia-Olivé, E Monsó, F Andreo, J Sanz-Santos, M Taron, ... European Respiratory Journal 35 (2), 391-395, 2010 | 154 | 2010 |
| A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells MA Molina-Vila, J Bertran-Alamillo, N Reguart, M Taron, E Castella, ... Journal of Thoracic Oncology 3 (11), 1224-1235, 2008 | 134 | 2008 |
| Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer S Simonetti, MA Molina, C Queralt, I de Aguirre, C Mayo, ... Journal of translational medicine 8, 1-8, 2010 | 116 | 2010 |
| Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib … N Reguart, R Rosell, F Cardenal, AF Cardona, D Isla, R Palmero, T Moran, ... Lung cancer 84 (2), 161-167, 2014 | 96 | 2014 |
| Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer R Rosell, Y Ichinose, M Taron, C Sarries, C Queralt, P Mendez, ... Lung cancer 50 (1), 25-33, 2005 | 89 | 2005 |
| Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin–treated advanced non–small-cell lung cancer patients C Camps, C Sarries, B Roig, JJ Sánchez, C Queralt, E Sancho, ... Clinical lung cancer 4 (4), 237-241, 2003 | 75 | 2003 |
| Serum DNA as a tool for cancer patient management JL Ramirez, M Taron, C Balana, C Sarries, P Mendez, I de Aguirre, ... Rocz Akad Med Bialymst 48 (2), 34-41, 2003 | 68 | 2003 |
